NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) |
|
|
| Recruiting | 3 | 288 | RoW | Disitamab vedotin, RC48, Endocrine therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HR Positive/HER2 Low Expression Metastatic Breast Cancer | 03/28 | 03/30 | | |